Q32 Bio (QTTB) Competitors $1.66 -0.11 (-6.21%) Closing price 05/21/2025 04:00 PM EasternExtended Trading$1.68 +0.02 (+1.27%) As of 09:19 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock QTTB vs. OCX, ADAG, CRVO, CRBP, TCRX, IMAB, JMAC, INZY, CRBU, and ADAPShould you be buying Q32 Bio stock or one of its competitors? The main competitors of Q32 Bio include OncoCyte (OCX), Adagene (ADAG), CervoMed (CRVO), Corbus Pharmaceuticals (CRBP), TScan Therapeutics (TCRX), I-Mab (IMAB), Maxpro Capital Acquisition (JMAC), Inozyme Pharma (INZY), Caribou Biosciences (CRBU), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "pharmaceutical products" industry. Q32 Bio vs. OncoCyte Adagene CervoMed Corbus Pharmaceuticals TScan Therapeutics I-Mab Maxpro Capital Acquisition Inozyme Pharma Caribou Biosciences Adaptimmune Therapeutics Q32 Bio (NASDAQ:QTTB) and OncoCyte (NASDAQ:OCX) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their valuation, profitability, institutional ownership, media sentiment, earnings, risk, community ranking, dividends and analyst recommendations. Which has higher earnings and valuation, QTTB or OCX? OncoCyte has higher revenue and earnings than Q32 Bio. OncoCyte is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioQ32 Bio-$6.65M-3.04-$112.96M-$4.94-0.34OncoCyte$3.84M22.85-$27.78M-$3.53-0.87 Which has more volatility and risk, QTTB or OCX? Q32 Bio has a beta of -0.02, meaning that its share price is 102% less volatile than the S&P 500. Comparatively, OncoCyte has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Is QTTB or OCX more profitable? Q32 Bio has a net margin of 0.00% compared to OncoCyte's net margin of -6,122.29%. Q32 Bio's return on equity of -146.18% beat OncoCyte's return on equity.Company Net Margins Return on Equity Return on Assets Q32 BioN/A -146.18% -54.49% OncoCyte -6,122.29%-269.32%-59.71% Do analysts prefer QTTB or OCX? Q32 Bio presently has a consensus target price of $24.71, suggesting a potential upside of 1,388.81%. OncoCyte has a consensus target price of $5.42, suggesting a potential upside of 76.44%. Given Q32 Bio's higher possible upside, equities research analysts clearly believe Q32 Bio is more favorable than OncoCyte.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Q32 Bio 0 Sell rating(s) 6 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25OncoCyte 0 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.67 Does the media favor QTTB or OCX? In the previous week, OncoCyte had 5 more articles in the media than Q32 Bio. MarketBeat recorded 5 mentions for OncoCyte and 0 mentions for Q32 Bio. OncoCyte's average media sentiment score of 0.52 beat Q32 Bio's score of 0.00 indicating that OncoCyte is being referred to more favorably in the news media. Company Overall Sentiment Q32 Bio Neutral OncoCyte Positive Do insiders & institutionals have more ownership in QTTB or OCX? 31.3% of Q32 Bio shares are held by institutional investors. Comparatively, 55.3% of OncoCyte shares are held by institutional investors. 40.0% of Q32 Bio shares are held by insiders. Comparatively, 1.6% of OncoCyte shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth. Does the MarketBeat Community believe in QTTB or OCX? OncoCyte received 2 more outperform votes than Q32 Bio when rated by MarketBeat users. However, 63.16% of users gave Q32 Bio an outperform vote while only 12.07% of users gave OncoCyte an outperform vote. CompanyUnderperformOutperformQ32 BioOutperform Votes1263.16% Underperform Votes736.84% OncoCyteOutperform Votes1412.07%Underperform Votes10287.93% SummaryOncoCyte beats Q32 Bio on 10 of the 17 factors compared between the two stocks. Get Q32 Bio News Delivered to You Automatically Sign up to receive the latest news and ratings for QTTB and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart QTTB vs. The Competition Export to ExcelMetricQ32 BioPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$20.25M$6.53B$5.38B$8.39BDividend YieldN/A2.64%5.21%4.10%P/E Ratio-0.128.9226.7619.71Price / Sales-3.04252.24389.71117.54Price / CashN/A65.8538.2534.62Price / Book0.076.466.784.50Net Income-$112.96M$143.98M$3.23B$248.18M7 Day Performance-4.60%2.03%1.51%0.23%1 Month Performance-13.09%4.11%10.03%12.39%1 Year Performance-94.42%-2.87%16.65%7.07% Q32 Bio Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)QTTBQ32 Bio2.1195 of 5 stars$1.66-6.2%$24.71+1,388.8%-94.5%$20.25M$-6,651,000.00-0.1239Gap DownOCXOncoCyte2.4132 of 5 stars$2.81-2.1%$4.42+57.2%+8.9%$80.36M$1.88M-0.64120Analyst ForecastGap DownADAGAdagene2.3111 of 5 stars$1.70+6.2%$8.00+370.9%-35.9%$80.04M$103,204.000.00260CRVOCervoMed3.3162 of 5 stars$9.10+7.2%$27.63+203.6%-56.2%$79.20M$7.14M-4.484Gap UpCRBPCorbus Pharmaceuticals4.5886 of 5 stars$7.16+11.0%$50.88+610.5%-83.6%$78.93MN/A-1.5340Positive NewsTCRXTScan Therapeutics3.9372 of 5 stars$1.37+7.9%$8.50+520.4%-85.8%$77.53M$4.42M-1.29100Positive NewsInsider TradeIMABI-Mab3.1896 of 5 stars$0.95+7.4%$5.50+482.0%-46.4%$77.02M$3.27M0.00380News CoverageJMACMaxpro Capital AcquisitionN/A$5.68flatN/A+1,580.3%$76.27MN/A0.002,021Gap UpINZYInozyme Pharma2.8857 of 5 stars$1.18+2.6%$14.63+1,139.4%-16.0%$76.18MN/A-0.7650CRBUCaribou Biosciences2.7545 of 5 stars$0.82+5.7%$9.33+1,040.9%-67.2%$76.09M$9.99M-0.50100ADAPAdaptimmune Therapeutics2.7357 of 5 stars$0.30+0.9%$1.83+519.9%-74.5%$75.94M$178.03M-1.34490 Related Companies and Tools Related Companies OncoCyte Competitors Adagene Competitors CervoMed Competitors Corbus Pharmaceuticals Competitors TScan Therapeutics Competitors I-Mab Competitors Maxpro Capital Acquisition Competitors Inozyme Pharma Competitors Caribou Biosciences Competitors Adaptimmune Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:QTTB) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | SponsoredThe Prophet's Newest PredictionA storm is brewing in the markets: new tariffs, recession warnings, and panic in the headlines. That’s when pu...Stansberry Research | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredFeds Just Admitted It—They Can Take Your CashThe Government Just Said Your Money Isn't Yours That's right—According to the DOJ, YOUR hard-earned money i...Priority Gold | SponsoredThis Is The Moment You Betray Trump (Or Prove Them Wrong)They said you wouldn’t last—that Bidenflation, Wall Street selloffs, and DEI funds would break your loyalty to...Colonial Metals | SponsoredTrump + Musk = AI’s turning pointTrump may not code… but he knows how to pick winners. And according to insiders, his administration is prep...True Market Insiders | SponsoredThe Collapse Has Already Started — Your 401(k) Is NextThere's a major heist happening on American wealth in real time. Except this one doesn't involve masks or v...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Q32 Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy QTTB Stock Free QTTB Stock Alerts